Drug‐Eluting Stents

Seidlitz, Anne

doi:10.1002/9781118675748.ch4

Cited by 4 publications

(5 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DESs were mainly adopted as a solution for in-stent restenosis, a major problem associated with the stenting procedure [ 52 ]. Their proven long-term safety and efficacy are also reflected in the improved subsequent revascularization rates and reduced risk of thrombosis compared to BMSs [ 53 , 54 , 55 , 56 ].…”

Section: Evolution Of Cardiovascular Stentsmentioning

confidence: 99%

“…Regarding the incorporated drugs, new substances have been proposed in these stents, such as zotarolimus, everolimus, and novolimus [ 6 , 68 , 69 , 70 , 71 , 72 ]. Through their diffusion into the vessel wall, these compounds lead to good endothelial coverage, inhibition of vascular restenosis, and suppression of transplant rejection [ 20 , 22 , 52 , 63 ]. Moreover, drug diffusivity is highly dependent on the size and charge of the drug.…”

Section: Evolution Of Cardiovascular Stentsmentioning

confidence: 99%

“…Such devices allow localized elution over the course of a month of neointimal inhibiting drugs, such as sirolimus and paclitaxel, which have antiproliferative effects [46][47][48][49]. DESs were mainly adopted as a solution for in-stent restenosis, a major problem associated with the stenting procedure [52]. Their proven long-term safety and efficacy are also reflected in the improved subsequent revascularization rates and reduced risk of thrombosis compared to BMSs [53][54][55][56].…”

Section: Drug-eluting Stentsmentioning

confidence: 99%

See 2 more Smart Citations

Cardiovascular Stents: A Review of Past, Current, and Emerging Devices

et al. 2021

View full text Add to dashboard Cite

One of the leading causes of morbidity and mortality worldwide is coronary artery disease, a condition characterized by the narrowing of the artery due to plaque deposits. The standard of care for treating this disease is the introduction of a stent at the lesion site. This life-saving tubular device ensures vessel support, keeping the blood-flow path open so that the cardiac muscle receives its vital nutrients and oxygen supply. Several generations of stents have been iteratively developed towards improving patient outcomes and diminishing adverse side effects following the implanting procedure. Moving from bare-metal stents to drug-eluting stents, and recently reaching bioresorbable stents, this research field is under continuous development. To keep up with how stent technology has advanced in the past few decades, this paper reviews the evolution of these devices, focusing on how they can be further optimized towards creating an ideal vascular scaffold.

show abstract

Section: Evolution Of Cardiovascular Stentsmentioning

confidence: 99%

Section: Evolution Of Cardiovascular Stentsmentioning

confidence: 99%

Section: Drug-eluting Stentsmentioning

confidence: 99%

See 1 more Smart Citation

Cardiovascular Stents: A Review of Past, Current, and Emerging Devices

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Drug-eluting stents (DES), in particular those of newer generations, are superior to bare metal stents in the treatment of coronary artery stenosis [ 1 , 2 , 3 , 4 , 5 ]. Among others, frequently used drugs are from the Limus family, especially sirolimus (SIR) [ 6 , 7 , 8 , 9 ], but also paclitaxel (PTX) [ 10 ], dexamethasone (DEX) [ 11 , 12 ], and cyclosporine A (CYCLO) [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Influence of Drug Incorporation on the Physico-Chemical Properties of Poly(l-Lactide) Implant Coating Matrices—A Systematic Study

et al. 2021

View full text Add to dashboard Cite

Local drug delivery has become indispensable in biomedical engineering with stents being ideal carrier platforms. While local drug release is superior to systemic administration in many fields, the incorporation of drugs into polymers may influence the physico-chemical properties of said matrix. This is of particular relevance as minimally invasive implantation is frequently accompanied by mechanical stresses on the implant and coating. Thus, drug incorporation into polymers may result in a susceptibility to potentially life-threatening implant failure. We investigated spray-coated poly-l-lactide (PLLA)/drug blends using thermal measurements (DSC) and tensile tests to determine the influence of selected drugs, namely sirolimus, paclitaxel, dexamethasone, and cyclosporine A, on the physico-chemical properties of the polymer. For all drugs and PLLA/drug ratios, an increase in tensile strength was observed. As for sirolimus and dexamethasone, PLLA/drug mixed phase systems were identified by shifted drug melting peaks at 200 °C and 240 °C, respectively, whereas paclitaxel and dexamethasone led to cold crystallization. Cyclosporine A did not affect matrix thermal properties. Altogether, our data provide a contribution towards an understanding of the complex interaction between PLLA and different drugs. Our results hold implications regarding the necessity of target-oriented thermal treatment to ensure the shelf life and performance of stent coatings.

show abstract

“…Liposomes can be used with polymer-coated stents or as a stand-alone drug delivery mechanism. Stents coated with polymeric material containing dispersed or encapsulated drugs have been developed as a method to prevent stent-related complications in a noninvasive manner [60]. The possibility of coating polymer-covered stents with liposomes encapsulating heparin to increase the hemocompatibility of polymer-covered stents was explored.…”

Section: Liposomes-drug/gene Delivery Systemsmentioning

confidence: 99%

Organic Nanoparticles in Progressing Cardiovascular Disease Treatment and Diagnosis

Udriște,

Burdușel,

Niculescu

et al. 2024

Polymers

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs), the world’s most prominent cause of mortality, continue to be challenging conditions for patients, physicians, and researchers alike. CVDs comprise a wide range of illnesses affecting the heart, blood vessels, and the blood that flows through and between them. Advances in nanomedicine, a discipline focused on improving patient outcomes through revolutionary treatments, imaging agents, and ex vivo diagnostics, have created enthusiasm for overcoming limitations in CVDs’ therapeutic and diagnostic landscapes. Nanomedicine can be involved in clinical purposes for CVD through the augmentation of cardiac or heart-related biomaterials, which can be functionally, mechanically, immunologically, and electrically improved by incorporating nanomaterials; vasculature applications, which involve systemically injected nanotherapeutics and imaging nanodiagnostics, nano-enabled biomaterials, or tissue-nanoengineered solutions; and enhancement of sensitivity and/or specificity of ex vivo diagnostic devices for patient samples. Therefore, this review discusses the latest studies based on applying organic nanoparticles in cardiovascular illness, including drug-conjugated polymers, lipid nanoparticles, and micelles. Following the revised information, it can be concluded that organic nanoparticles may be the most appropriate type of treatment for cardiovascular diseases due to their biocompatibility and capacity to integrate various drugs.

show abstract

Drug‐Eluting Stents

Cited by 4 publications

References 110 publications

Cardiovascular Stents: A Review of Past, Current, and Emerging Devices

Cardiovascular Stents: A Review of Past, Current, and Emerging Devices

Influence of Drug Incorporation on the Physico-Chemical Properties of Poly(l-Lactide) Implant Coating Matrices—A Systematic Study

Organic Nanoparticles in Progressing Cardiovascular Disease Treatment and Diagnosis

Contact Info

Product

Resources

About